高级检索
当前位置: 首页 > 详情页

Progress in the correlation between PTPN12 gene expression and human tumors

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Breast & Thyroid Surg, Shanghai, Peoples R China [2]Hebei Med Univ, Sch Basic Med Sci, 361 Zhongshan East Rd, Shijiazhuang, Hebei, Peoples R China [3]Hebei Med Univ, Hosp 4, Dept Urinary Surg, 12 Jiankang Rd, Shijiazhuang 050000, Hebei, Peoples R China
出处:
ISSN:

关键词: proto-oncogenes protein tyrosine phosphatase non-receptor type 12 renal cell carcinoma tumor tumor suppressor genes

摘要:
Background: The global morbidity of cancer is rising rapidly. Despite advances in molecular biology, immunology, and cytotoxic and immune-anticancer therapies, cancer remains a major cause of death worldwide. Protein tyrosine phosphatase non-receptor type 12 (PTPN12) is a new member of the cytoplasmic protein tyrosine phosphatase family, isolated from a cDNA library of adult colon tissue. Thus far, no studies have reviewed the correlation between PTPN12 gene expression and human tumors. Methods: This article summarizes the latest domestic and international research developments on how the expression of PTPN12 relates to human tumors. The extensive search in Web of Science and PubMed with the keywords including PTPN12, tumor, renal cell carcinoma, proto-oncogenes, tumor suppressor genes was undertaken. Results: More and more studies have shown that a tumor is essentially a genetic disease, arising from a broken antagonistic function between proto-oncogenes and tumor suppressor genes. When their antagonistic effect is out of balance, it may cause uncontrolled growth of cells and lead to the occurrence of tumors. PTPN12 is a tumor suppressor gene, so inhibiting its activity will lead directly or indirectly to the occurrence of tumors. Conclusion: The etiology, prevention, and treatment of tumors have become the focus of research around the world. PTPN12 is a tumor suppressor gene. In the future, PTPN12 might serve as a novel molecular marker to benefit patients, and even the development of tumor suppressor gene activation agents can form a practical research direction.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2020]版:
Q3 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Breast & Thyroid Surg, Shanghai, Peoples R China
通讯作者:
通讯机构: [3]Hebei Med Univ, Hosp 4, Dept Urinary Surg, 12 Jiankang Rd, Shijiazhuang 050000, Hebei, Peoples R China [*1]Department of Urinary Surgery, The fourth hospital of Hebei medical university, No.12 Jiankang Road, 050000, P. R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号